The DOI matches its Crossref record.
α1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients
Open accessAbstract
The airways of cystic fibrosis (CF) patients are characterised by neutrophils that release high amounts of elastase overwhelming the local antiprotease shield. Inhalation of α 1-antitrypsin (AAT) may restore the protease–antiprotease balance and attenuate airway inflammation in CF airways. The aims of the present study were: 1) to assess the best deposition region for inhaled AAT by two different inhalation strategies; and 2) to examine the effect of 4 weeks of AAT inhalation on lung function, protease–antiprotease balance and airway inflammation in CF patients. In a prospective, randomised study, 52 CF patients received a daily deposition by inhalation of 25 mg AAT for 4 weeks targeting their peripheral or bronchial compartment. The levels of elastase activity, AAT, pro-inflammatory cytokines, neutrophils, immunoglobulin G fragments and the numbers of Pseudomonas aeruginosa were assessed in induced sputum before and after the inhalation period. Inhalation of AAT increased AAT levels and decreased the levels of elastase activity, neutrophils, pro-inflammatory cytokines and the numbers of P. aeruginosa. However, it had no effect on lung function. No difference was found between the peripheral and bronchial inhalation mode. In conclusion, although no effect on lung function was observed, the clear reduction of airway inflammation after α 1-antitrypsin treatment may precede pulmonary structural changes. The α 1-antitrypsin deposition region may play a minor role for α 1-antitrypsin inhalation in cystic fibrosis patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy
Cantin, A. M., Hartl, D., Konstan, M. W., & Chmiel, J. F. (2015) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2015.03.003 · Cited by 496
Self-citationProgress in therapies for cystic fibrosis
De Boeck, K., & Amaral, M. D. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)00023-0 · Cited by 451
The discovery of α1-antitrypsin and its role in health and disease
Janciauskiene, S. M., Bals, R., Koczulla, R., Vogelmeier, C., Köhnlein, T., & Welte, T. (2011) · Respiratory Medicine · doi:10.1016/j.rmed.2011.02.002 · Cited by 348
Greene, C. M., Marciniak, S. J., Teckman, J., Ferrarotti, I., Brantly, M. L., Lomas, D. A., Stoller, J. K., & McElvaney, N. G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.51 · Cited by 324
Heijerman, H., Westerman, E., Conway, S., & Touw, D. (2009) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2009.04.005 · Cited by 264
Metadata
- Authors
- Griese, M., Latzin, P., Kappler, M., Weckerle, K., Heinzlmaier, T., Bernhardt, T., & Hartl, D.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2006-10-18
- Volume
- 29
- Issue
- 2
- Pages
- 240-250
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2131008616
- Cited by
- 198
- References
- 0
- FWCI
- 8.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: α1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. https://app.cochat.ai/papers/10.1183/09031936.00047306
- The paper
- Griese, M., Latzin, P., Kappler, M., Weckerle, K., Heinzlmaier, T., Bernhardt, T., & Hartl, D. (2007). α1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. European Respiratory Journal. https://doi.org/10.1183/09031936.00047306
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.